Galantamine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Galantamine

Examples of brand names: Reminyl [DE]

ATC code: N06DA04

Main use (for orientation): Alzheimer's dementia

Documented research summary

Thirty participants with cannabis use disorder received galantamine or placebo for ten days; there was no acute cannabis challenge and no established between-group difference in cognition. Galantamine in cannabinoid enzyme tests is a positive control, not a tested combination.

Uncertainties and limitations

Documented individual title/abstract review with selected relevant full texts; not an exhaustive worldwide systematic review and no independent human professional approval. Missing data do not establish safety. All 28 cannabinoids define the search scope, not 28 clinically studied pairs per active substance.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

Cannabis use disorder; no standardised acute cannabinoid administration – insufficient evidence

Finding ID: B0478

Type of result: No isolated investigation of the pair

Observation: No clear cognitive difference between galantamine and placebo was demonstrated.

Mechanism: Galantamine was used to investigate cognition in a population with cannabis use disorder, not standardised pair pharmacokinetics.

Study type: Small randomised study in the context of cannabis use disorder

Context studied: 30 people; 8 mg galantamine daily for ten days.

Clinical interpretation: No isolated investigation of the pair; clinical relevance as a medicine–cannabinoid interaction cannot be determined.

Limitations and uncertainties: No acute cannabis challenge; do not interpret this as evidence of the safety of a galantamine–cannabinoid combination.

Original sources for this finding: Feasibility and effects of galantamine on cognition in humans with cannabis use disorder. [VF_P_31082417]

References and access status

[VF_L_D0414] Galantamine 4mg/ml Oral Solution - Summary of Product Characteristics (SmPC) - (emc) | 10499

Original source / bibliographic reference

Authors: Marketing authorisation holder; product information via emc

Year: 2026

Source type: Official medicine information; relevant identity, PK, PD and DDI sections read individually

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VF_P_31082417] Feasibility and effects of galantamine on cognition in humans with cannabis use disorder.

Original source / bibliographic reference

Authors: Sugarman DE, De Aquino JP, Poling J, Sofuoglu M.

Year: 2019

Source type: Scientific publication; precise study type and suitability described in the finding or individual review

DOI: 10.1016/j.pbb.2019.05.004

PMID: 31082417

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility